Welcome to our dedicated page for Bridgebio Pharma news (Ticker: BBIO), a resource for investors and traders seeking the latest updates and insights on Bridgebio Pharma stock.
BridgeBio Pharma, Inc. develops and commercializes medicines for genetic conditions through a decentralized biopharmaceutical model. News for BBIO centers on Attruby/acoramidis, its oral transthyretin stabilizer for transthyretin amyloid cardiomyopathy (ATTR-CM), including clinical data from ATTRibute-CM, commercial updates, Brazil marketing authorization under the BEYONTTRA name, and licensing or commercialization arrangements.
Company updates also cover late-stage genetic-disease programs such as encaleret for autosomal dominant hypocalcemia type 1, BBP-418 for limb-girdle muscular dystrophy type 2I/R9, and oral infigratinib for achondroplasia. Recurring financial and corporate items include quarterly results, product revenue trends, capital actions, employee equity inducement grants, investor conference participation, and pipeline regulatory disclosures.
BridgeBio Oncology Therapeutics (BBOT) and Helix Acquisition Corp. II (HLXB) have announced a business combination agreement to create a publicly listed biotechnology company. The transaction, expected to complete in Q3 2025, will provide total proceeds of $450 million, combining HLXB's trust account funds and a $260 million PIPE financing led by Cormorant Asset Management.
The combined entity will focus on developing therapies for RAS and PI3Kα malignancies through three lead programs:
- BBO-8520: A KRASG12C inhibitor in Phase 1 trials for non-small cell lung cancer
- BBO-10203: An oral small molecule in Phase 1 trials for various cancers
- BBO-11818: A pan-KRAS inhibitor expected to begin patient dosing in H1 2025
The combined company is projected to have an implied pro forma equity value of $949 million at closing, assuming a $10.36 share price and no redemptions. BBOT shareholders will roll 100% of their equity into the combined company.
BridgeBio Pharma (BBIO) has priced a $500 million convertible senior notes offering due 2031, with an additional $75 million option for initial purchasers. The notes, priced at a 1.75% interest rate with a 45% conversion premium, will be convertible into cash, company shares, or a combination thereof.
The company expects net proceeds of approximately $489.5 million (or $563.0 million if the additional option is exercised). These funds will be used to repay outstanding borrowings under its Financing Agreement with Blue Owl , which accounted for $51.5 million in interest payments in 2024. Additionally, $48.3 million will be used to repurchase 1,405,411 shares at $34.35 per share.
The notes will mature on March 1, 2031, with an initial conversion rate of 20.0773 shares per $1,000 principal amount, equivalent to a conversion price of $49.81 per share.
BridgeBio Pharma (BBIO) has announced plans to offer $500 million in convertible senior notes due 2031, with an additional $75 million option for initial purchasers. The company will use the proceeds to repay outstanding borrowings under its Financing Agreement with Blue Owl , which accounted for approximately $51.5 million in interest payments in 2024.
The company plans to use up to $50 million to repurchase shares of its common stock from certain note purchasers in private transactions. The notes will mature on March 1, 2031, bearing semi-annual interest, and will be convertible into cash, shares, or a combination thereof. BridgeBio may redeem the notes after March 6, 2028, if the stock price exceeds 130% of the conversion price for a specified period.
This refinancing strategy aims to strengthen the balance sheet without increasing total liabilities, while lowering interest expenses and extending debt maturity.
BridgeBio Pharma (BBIO) reported its Q4 and full-year 2024 results, highlighting significant progress with Attruby™. Since FDA approval in November 2024, 1,028 unique patient prescriptions have been written by 516 prescribers. The drug was also approved as BEYONTTRA™ in the EU in February 2025, triggering a $75 million milestone payment.
The company ended Q4 2024 with $681.2 million in cash, up from $392.6 million year-over-year. Revenue for 2024 increased to $221.9 million from $9.3 million in 2023, primarily due to licensing agreements and initial Attruby sales. Operating expenses rose to $814.9 million in 2024 from $616.7 million in 2023.
Three global registrational studies are fully enrolled: FORTIFY, CALIBRATE, and PROPEL 3, with results expected before end of 2025. The company expects to receive $105 million in regulatory milestones in H1 2025 from acoramidis approvals in Europe and Japan.
BridgeBio Pharma (BBIO) has announced it will release its Q4 and full-year 2024 financial results on February 20, 2025. The announcement will include updates on Attruby's commercialization progress and the company's late-stage clinical pipeline. Starting with Q1 results, expected in late April or early May, the company will begin hosting earnings calls, as previously outlined in its JPM presentation.
BridgeBio Pharma (BBIO) has received European Commission approval for BEYONTTRA™ (acoramidis), the first near-complete TTR stabilizer (≥90%) to treat ATTR-CM, a fatal heart condition. The approval is based on the Phase 3 ATTRibute-CM study results, which showed:
- 42% reduction in composite all-cause mortality and recurrent cardiovascular-related hospitalization events at Month 30
- 50% reduction in cumulative frequency of cardiovascular-related hospitalization events at Month 30
- Benefits observed in as few as 3 months
Following the approval, BridgeBio will receive a $75 million milestone payment from Bayer, who will handle EU commercialization. BridgeBio will also receive tiered royalties starting in the low-thirties percent on EU sales. Bayer plans to launch the drug in the first half of 2025. The drug was previously approved in the U.S. as Attruby™ in November 2024, with 430 patient prescriptions written by 248 physicians since approval.
BridgeBio Pharma (NASDAQ: BBIO) reported significant commercial progress for its recently FDA-approved drug Attruby, with 430 prescriptions written by 248 unique physicians for ATTR-CM treatment. The company announced the completion of enrollment in three major Phase 3 clinical trials: FORTIFY (112 patients for LGMD2I/R9), CALIBRATE (70 patients for ADH1), and PROPEL 3 (114 participants for achondroplasia).
The company's financial position is strong with $406 million in cash as of last quarter, plus $500 million received upon Attruby's FDA approval from a royalty facility. BridgeBio anticipates an additional $105 million in regulatory milestones in the first half of 2025 from expected European and Japanese approvals of acoramidis. All three Phase 3 trials are expected to reach significant milestones in the second half of 2025.
BridgeBio Pharma (Nasdaq: BBIO), a biopharmaceutical company specializing in genetic diseases, has announced its participation in the 43rd Annual J.P. Morgan Healthcare Conference in San Francisco. Co-founder and CEO Neil Kumar, Ph.D., will deliver a presentation on Monday, January 13 at 7:30 am PT.
Investors and interested parties can access the live webcast through the 'Events & Presentations' section of BridgeBio's investor website. The presentation recording will remain available for 30 days following the event on the company's website.
BridgeBio Pharma (BBIO) announced that the Committee for Medicinal Products for Human Use (CHMP) has recommended approval of acoramidis in the EU for treating transthyretin amyloid cardiomyopathy (ATTR-CM). The recommendation follows positive Phase 3 ATTRibute-CM study results, showing a 42% reduction in composite all-cause mortality and recurrent cardiovascular-related hospitalization events, and a 50% reduction in cumulative frequency of cardiovascular-related hospitalization events at Month 30.
The drug was already approved by the FDA on November 22, 2024, as Attruby™, becoming the first ATTR-CM treatment achieving near-complete stabilization in the US. Through a collaboration with Bayer, BridgeBio holds US marketing rights while Bayer manages European distribution. Following expected European Commission approval, Bayer plans to launch acoramidis in Europe in first half 2025.
BridgeBio Pharma announced FDA approval of Attruby™ (acoramidis) for treating adults with ATTR-CM to reduce cardiovascular death and hospitalization. The approval is based on the ATTRibute-CM Phase 3 study results, showing a 42% reduction in composite all-cause mortality and recurrent cardiovascular-related hospitalizations at Month 30. Attruby demonstrated rapid benefits within 3 months and achieved a 50% reduction in cardiovascular-related hospitalization events. As the first approved product with near-complete TTR stabilization (≥90%), Attruby preserves native TTR function. BridgeBio will receive a $500 million payment under their royalty funding agreement and has submitted for European approval, expected in 2025.